Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Unmaintained remissions in multiple myeloma.

R Alexanian, E Gehan, A Haut

    Blood
    |June 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Value of novel agents and intensive therapy for patients with multiple myeloma.

    Bone marrow transplantation·2013
    Same author

    [Comment on the contribution by Erna J. Schilder (1988): Restraining patients? A study of the use of restraints in nursing]].

    Pflege·2012
    Same author

    Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).

    Hematology (Amsterdam, Netherlands)·2010
    Same author

    CR represents an early index of potential long survival in multiple myeloma.

    Bone marrow transplantation·2009
    Same author

    Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.

    Hematology (Amsterdam, Netherlands)·2007
    Same author

    International uniform response criteria for multiple myeloma.

    Leukemia·2006

    Selected multiple myeloma patients can achieve long remissions without continuous chemotherapy. Relapse can be effectively managed by resuming melphalan-prednisone treatment, supporting careful monitoring strategies.

    Area of Science:

    • Hematology
    • Oncology
    • Clinical Medicine

    Background:

    • Multiple myeloma treatment often involves melphalan-prednisone combinations.
    • Assessing the efficacy of unmaintained remission in multiple myeloma is crucial for treatment strategies.

    Purpose of the Study:

    • To evaluate the survival and remission duration in multiple myeloma patients after initial treatment with melphalan-prednisone.
    • To determine the impact of unmaintained remission on disease progression and retreatment outcomes.

    Main Methods:

    • Follow-up study of 28 multiple myeloma patients post-melphalan-prednisone therapy.
    • Comparison of survival times between patients receiving no further treatment versus continuous chemotherapy.
    • Analysis of factors influencing unmaintained remission duration and response to retreatment.

    Related Experiment Videos

    Main Results:

    • Patients with unmaintained remission showed similar survival to those on continuous chemotherapy.
    • Prolonged unmaintained remissions were observed in patients with less extensive disease or complete protein normalization.
    • Resumption of melphalan-prednisone effectively controlled initial relapse in 80% of patients, though subsequent remissions were shorter.

    Conclusions:

    • Selected multiple myeloma patients with low plasma cell counts may benefit from long-term monitoring without continuous chemotherapy.
    • Unmaintained remission strategies can be viable for patients likely to achieve disease stability and respond to retreatment.
    • This approach supports individualized treatment plans in multiple myeloma management.